On 10 September 2026, the National Commission into the Regulation of AI in Healthcare published a landmark blueprint setting out comprehensive reforms to accelerate the safe, transparent deployment of artificial intelligence across the NHS. Aimed at balancing rapid clinical innovation with robust patient safety, the blueprint calls for a fundamental overhaul of medical device approvals for algorithmic diagnostic and triage tools.
The ‘L-Plate’ provisional licensing system
A centerpiece of the Commission’s recommendations is the introduction of a staged, “L-plate” conditional authorization framework for novel medical AI models. Rather than granting permanent certification based solely on historical benchmark datasets, the proposed regime mandates:
- Controlled deployment phases: New clinical algorithms will be deployed initially within ring-fenced clinical environments under mandatory specialist supervision.
- Real-world efficacy milestones: Progression to unrestricted clinical deployment will require demonstrated diagnostic accuracy and safety outcomes in live hospital workflows.
- Early withdrawal powers: Authorisations can be suspended immediately if algorithmic drift or unexpected diagnostic disparities occur in clinical practice.
Continuous monitoring and enhanced MHRA enforcement
The report addresses a critical shortcoming of traditional medical device regulation: unlike physical hardware, AI models are dynamic, susceptible to software updates, changing patient demographics, and distributional shift.
To counter these risks, the Commission recommends granting the Medicines and Healthcare products Regulatory Agency (MHRA) expanded statutory powers:
- Mandatory post-market surveillance: Healthcare providers and AI developers must maintain real-time telemetry and report clinical discrepancies into a centralised national incident register.
- Substantial financial penalties: The MHRA should be empowered to levy significant fines on manufacturers who conceal performance degradation or fail to report safety-critical incidents promptly.
- Public transparency index: Patients and clinicians will gain access to an open registry displaying verified accuracy metrics and safety warnings for every NHS-deployed AI system.
Strategic impact for medtech developers and NHS Trusts
For digital health enterprises and healthcare legal teams, these proposals signal a decisive shift from static compliance to ongoing operational accountability:
- Clinical safety governance: NHS Trusts must establish multidisciplinary algorithmic review boards to oversee AI performance within local clinical pathways.
- Contractual liability and indemnity: Procurement agreements must clearly delineate software defect liability between AI vendors and healthcare providers.
- Audit-ready documentation: Continuous verification logs, validation methodologies, and bias mitigation protocols will be required to maintain regulatory approval in the UK market.